In mouse melanoma models, activation of the β-catenin pathway in melanoma cells is associated with low/absent tumor-infiltrating lymphocytes (TILs) in tumors and resistance to anti-PD-L1/anti-CTLA-4 antibody therapy [11]. The gene discussed is CTLA4; the disease is melanoma.